CN102781447B - 用于治疗过度增生性疾病、自身免疫性疾病和心脏病的包含3-奎宁环酮衍生物的水溶液 - Google Patents

用于治疗过度增生性疾病、自身免疫性疾病和心脏病的包含3-奎宁环酮衍生物的水溶液 Download PDF

Info

Publication number
CN102781447B
CN102781447B CN201180006745.3A CN201180006745A CN102781447B CN 102781447 B CN102781447 B CN 102781447B CN 201180006745 A CN201180006745 A CN 201180006745A CN 102781447 B CN102781447 B CN 102781447B
Authority
CN
China
Prior art keywords
liquid composition
substituted
diseases
carbon
carbons
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201180006745.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN102781447A (zh
Inventor
S.拜斯特伦
C.利杰布里斯
N.卡兰-莱哈姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Apria Treatment Co Ltd
Original Assignee
Aprea AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aprea AB filed Critical Aprea AB
Priority to CN201610993086.1A priority Critical patent/CN106963759B/zh
Publication of CN102781447A publication Critical patent/CN102781447A/zh
Application granted granted Critical
Publication of CN102781447B publication Critical patent/CN102781447B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201180006745.3A 2010-01-21 2011-01-21 用于治疗过度增生性疾病、自身免疫性疾病和心脏病的包含3-奎宁环酮衍生物的水溶液 Active CN102781447B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610993086.1A CN106963759B (zh) 2010-01-21 2011-01-21 用于治疗过度增生性疾病、自身免疫性疾病和心脏病的包含3-奎宁环酮衍生物的水溶液

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US29696410P 2010-01-21 2010-01-21
EP10151326.5 2010-01-21
US61/296964 2010-01-21
EP10151326 2010-01-21
PCT/EP2011/050854 WO2011089234A2 (en) 2010-01-21 2011-01-21 Method and composition

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201610993086.1A Division CN106963759B (zh) 2010-01-21 2011-01-21 用于治疗过度增生性疾病、自身免疫性疾病和心脏病的包含3-奎宁环酮衍生物的水溶液

Publications (2)

Publication Number Publication Date
CN102781447A CN102781447A (zh) 2012-11-14
CN102781447B true CN102781447B (zh) 2016-11-23

Family

ID=42212171

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201180006745.3A Active CN102781447B (zh) 2010-01-21 2011-01-21 用于治疗过度增生性疾病、自身免疫性疾病和心脏病的包含3-奎宁环酮衍生物的水溶液
CN201610993086.1A Active CN106963759B (zh) 2010-01-21 2011-01-21 用于治疗过度增生性疾病、自身免疫性疾病和心脏病的包含3-奎宁环酮衍生物的水溶液

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201610993086.1A Active CN106963759B (zh) 2010-01-21 2011-01-21 用于治疗过度增生性疾病、自身免疫性疾病和心脏病的包含3-奎宁环酮衍生物的水溶液

Country Status (22)

Country Link
US (1) US9061016B2 (cg-RX-API-DMAC7.html)
EP (1) EP2525796B1 (cg-RX-API-DMAC7.html)
JP (2) JP5845193B2 (cg-RX-API-DMAC7.html)
KR (1) KR101727085B1 (cg-RX-API-DMAC7.html)
CN (2) CN102781447B (cg-RX-API-DMAC7.html)
AU (1) AU2011208681B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012017994B8 (cg-RX-API-DMAC7.html)
CA (1) CA2786824C (cg-RX-API-DMAC7.html)
CY (1) CY1117659T1 (cg-RX-API-DMAC7.html)
DK (1) DK2525796T3 (cg-RX-API-DMAC7.html)
ES (1) ES2578513T3 (cg-RX-API-DMAC7.html)
HU (1) HUE028285T2 (cg-RX-API-DMAC7.html)
IL (1) IL220318A (cg-RX-API-DMAC7.html)
IN (1) IN2012DN05192A (cg-RX-API-DMAC7.html)
PH (1) PH12012501402A1 (cg-RX-API-DMAC7.html)
PL (1) PL2525796T3 (cg-RX-API-DMAC7.html)
PT (1) PT2525796T (cg-RX-API-DMAC7.html)
RU (1) RU2571566C2 (cg-RX-API-DMAC7.html)
SG (1) SG182537A1 (cg-RX-API-DMAC7.html)
SM (1) SMT201600189B (cg-RX-API-DMAC7.html)
WO (1) WO2011089234A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201204424B (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106963759A (zh) * 2010-01-21 2017-07-21 阿普里有限公司 用于治疗过度增生性疾病、自身免疫性疾病和心脏病的包含3‑奎宁环酮衍生物的水溶液

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104860994A (zh) * 2014-02-20 2015-08-26 中国药科大学 3-奎宁环酮类含磷化合物的制备及其医药用途
CN109280056A (zh) * 2017-07-21 2019-01-29 上海时莱生物技术有限公司 手性3-奎宁环酮类化合物、制备方法及用途
EP3762035A4 (en) * 2018-03-09 2022-03-02 Texas Tech University System COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF ALT CANCER
US20220087987A1 (en) * 2018-12-27 2022-03-24 National Cancer Center A method for treating swi/snf complex-deficient cancers comprising glutathione (gsh) metabolic pathway inhibitor
WO2021053155A1 (en) 2019-09-18 2021-03-25 Aprea Therapeutics Ab Combination treatment with a p53 reactivator and an inhibitor of an antiapoptotic bcl-2 family protein
US20230089530A1 (en) * 2020-02-09 2023-03-23 Newave Pharmaceutical Inc. Quinuclidinone analogues as anticancer agents
CN111257458B (zh) * 2020-02-20 2022-07-22 北京鑫开元医药科技有限公司海南分公司 一种3-奎宁环酮盐酸盐的检测方法及应用
WO2021170772A1 (en) 2020-02-26 2021-09-02 Aprea Therapeutics Ab Combination treatment with a p53 reactivator and an inhibitor of cd47 mediated signaling
WO2021180338A1 (en) 2020-03-09 2021-09-16 Aprea Therapeutics Ab Combination treatment with a p53 reactivator and an inhibitor of dna methyltransferase post stem cell transplant

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005090341A1 (en) * 2004-03-22 2005-09-29 Aprea Ab Azabicyclooctan-3-one derivatives and use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3775418A (en) * 1970-07-15 1973-11-27 American Home Prod 3-((3-azaspiro(5,5)undecino)methyl)-3-quinuclidinol
CA2423192C (en) 2000-09-20 2010-11-23 Karolinska Innovations Ab 1-azabicyclo[2.2.2]octan-3-one derivatives and maleimide derivatives and their use for treating cancer tumors
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
RU2226288C2 (ru) 2001-07-10 2004-03-27 ОПТИВА, Инк. Многослойное оптическое покрытие
DE60306896T2 (de) 2002-02-21 2007-02-15 Aprea Ab Verwendung von niedermolekularen verbindungen zur herstellung eines medikaments zur behandlung von durch mutation p53-vermittelten erkrankungen
EP1605939B1 (en) 2003-03-24 2008-10-15 Aprea Ab Pharmaceutical use of 1-azabicyclo¬ 2.2.2 octanes and a method of testing compounds for the ability of activating inactive wt p53
JP2007269786A (ja) 2006-03-09 2007-10-18 Daiichi Sankyo Healthcare Co Ltd パンテチン含有経口液剤
JP2008001606A (ja) 2006-06-20 2008-01-10 Mitsubishi Pharma Corp ピラゾロン化合物を含有する水溶液剤
RU2419421C2 (ru) 2006-07-18 2011-05-27 Хенфарма Лабораторио С.Л. Инъецируемая жидкая композиция парацетамола
JP2008201778A (ja) * 2007-01-25 2008-09-04 Mochida Pharmaceut Co Ltd バンコマイシン液状製剤
ES2384906T3 (es) 2007-03-01 2012-07-13 Novartis Ag Mesilato de etilamida del ácido 5-(2,4-dihidroxi-5-isopropil-fenil)-4-(4-morfolin-4-il-metil-fenil)-isoxazol-3-carboxílico, hidratos y polimorfos del mismo y formulaciones que comprenden estas formas
WO2011089234A2 (en) * 2010-01-21 2011-07-28 Aprea Ab Method and composition

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005090341A1 (en) * 2004-03-22 2005-09-29 Aprea Ab Azabicyclooctan-3-one derivatives and use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
In vitro and in vivo cytotoxic effects of PRIMA-1 on hepatocellular carcinoma cells expressing mutant p53ser249;Hong Shi，et al;《Carcinogenesis》;20071128;第29卷(第7期);第1428-1434页 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106963759A (zh) * 2010-01-21 2017-07-21 阿普里有限公司 用于治疗过度增生性疾病、自身免疫性疾病和心脏病的包含3‑奎宁环酮衍生物的水溶液
CN106963759B (zh) * 2010-01-21 2020-07-07 阿普利亚治疗有限公司 用于治疗过度增生性疾病、自身免疫性疾病和心脏病的包含3-奎宁环酮衍生物的水溶液

Also Published As

Publication number Publication date
JP5845193B2 (ja) 2016-01-20
US9061016B2 (en) 2015-06-23
BR112012017994A2 (pt) 2016-05-03
US20120289503A1 (en) 2012-11-15
EP2525796B1 (en) 2016-03-30
CA2786824C (en) 2018-04-10
ZA201204424B (en) 2013-08-28
BR112012017994B1 (pt) 2020-01-14
EP2525796A2 (en) 2012-11-28
HUE028285T2 (en) 2016-12-28
CN106963759A (zh) 2017-07-21
ES2578513T3 (es) 2016-07-27
WO2011089234A3 (en) 2011-10-06
IL220318A (en) 2015-10-29
CY1117659T1 (el) 2017-05-17
SG182537A1 (en) 2012-08-30
JP6106228B2 (ja) 2017-03-29
PH12012501402A1 (en) 2016-07-27
WO2011089234A8 (en) 2012-09-07
AU2011208681A1 (en) 2012-07-05
RU2012135698A (ru) 2014-02-27
KR101727085B1 (ko) 2017-04-14
AU2011208681B2 (en) 2014-10-23
SMT201600189B (it) 2016-08-31
DK2525796T3 (en) 2016-07-04
BR112012017994B8 (pt) 2020-12-08
CN102781447A (zh) 2012-11-14
PL2525796T3 (pl) 2016-09-30
WO2011089234A2 (en) 2011-07-28
JP2016020356A (ja) 2016-02-04
KR20120123441A (ko) 2012-11-08
RU2571566C2 (ru) 2015-12-20
PT2525796T (pt) 2016-07-11
CA2786824A1 (en) 2011-07-28
CN106963759B (zh) 2020-07-07
IN2012DN05192A (cg-RX-API-DMAC7.html) 2015-10-23
JP2013518036A (ja) 2013-05-20
AU2011208681A8 (en) 2013-01-31

Similar Documents

Publication Publication Date Title
CN106963759B (zh) 用于治疗过度增生性疾病、自身免疫性疾病和心脏病的包含3-奎宁环酮衍生物的水溶液
ES2767880T3 (es) Composiciones inyectables de melfalán que comprenden un derivado de ciclodextrina y métodos de preparación y uso de las mismas
CN114126596A (zh) 用于皮下注射的氯胺酮制剂
WO2003047587A1 (en) Platinum derivative pharmaceutical formulations
JPWO2008023807A1 (ja) 安定化された医薬組成物
JP2020125359A (ja) ペメトレキセドまたはその薬剤学的に許容可能な塩を含有する安定化された薬学組成物
US20220062294A1 (en) Pharmaceutical compositions of tetracyclic quinolone analogs and their salts
TW201141472A (en) Method to treat small cell lung cancer
EP2934593B1 (en) Cabazitaxel composition
BR112017024126B1 (pt) Composições farmacêuticas, composto a micronizado e/ou pelo menos um sal farmaceuticamente aceitável micronizado do composto a e uso dos mesmos
ES3056897T3 (en) Rifabutin compositions and method of making
US20100260832A1 (en) Combination therapy for ovarian cancer
IL289806B2 (en) Sodium salt of (e)-2,4,6-trimethoxystyryl-3-[(carboxymethyl)amino]-4-methoxybenzylsulphone for use in a method for treating conditions mediated by the rapid proliferation of abnormal cells, which includes oral administration of specific doses before breakfast and after lunch
TW202203938A (zh) 鹼性化學療法瘤內注射調配物
HK1236852B (en) Aqueous solution comprising 3-quinuclidinone derivative for the treatment of hyperproliferative diseases, autoimmune diseases and heart diseases
HK1236852A1 (en) Aqueous solution comprising 3-quinuclidinone derivative for the treatment of hyperproliferative diseases, autoimmune diseases and heart diseases
JP7606633B2 (ja) 医薬組成物及びアプレピタント注射液並びに凍結乾燥粉末注射剤
WO2019220961A1 (ja) ダリナパルシンのアルカリ金属塩及び／又は無機酸付加塩の結晶型及びその製剤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CP01 Change in the name or title of a patent holder

Address after: Solna, Sweden

Patentee after: APRIA TREATMENT CO., LTD.

Address before: Solna, Sweden

Patentee before: Aprea AB

CP01 Change in the name or title of a patent holder